<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406107</url>
  </required_header>
  <id_info>
    <org_study_id>PRC-001</org_study_id>
    <secondary_id>Pfizer Reference # 20050548</secondary_id>
    <nct_id>NCT00406107</nct_id>
  </id_info>
  <brief_title>Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion</brief_title>
  <official_title>Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palmetto Retina Center, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eyetech Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Palmetto Retina Center, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of intravitreal injections of Macugen
      every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion
      (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that
      chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinal venous occlusive disease, which includes central retinal vein occlusion (CRVO) and
      branch retinal vein occlusion (BRVO), is second only to diabetic retinopathy as a cause of
      vision loss due to retinal disease. The main cause of vision loss in all of these disorders
      is the development of macular edema. Current clinical practice based on randomized controlled
      clinical trials (ETDRS, BVOS) employs laser photocoagulation, either in a focal or grid
      pattern, to treat macular edema associated with diabetic retinopathy and branch retinal vein
      occlusion. Unfortunately, laser photocoagulation is ineffective in central retinal vein
      occlusion (CRVO), and no proven therapy exists for CRVO.

      The pathogenesis of macular edema in retinal vascular diseases is generally accepted to be
      increased levels of vascular endothelial growth factor (VEGF) due to ischemic or other
      stimuli. VEGF is known to be one of the most potent stimulators of vascular leakage in
      humans. Therefore, it seems sensible to study inhibition of VEGF to reduce vascular leakage,
      reduce macular edema, and improve vision in these retinal vascular disorders.

      Phase 2 randomized, controlled clinical trials of Macugen in diabetic macular edema and in
      macular edema associated with CRVO have been conducted. In the diabetes trial, patients
      treated with Macugen had improved vision, reduced macular edema as measured by optical
      coherence tomography (OCT), and reduced need for laser treatment compared to patients treated
      with sham injections. In the CRVO trial, patients treated with Macugen 1 mg every 6 weeks for
      24 weeks had improved vision and reduced macular edema at week 30 compared to sham. This is
      the first randomized trial of treatment for CRVO to show a benefit over control. Based on
      these positive findings, we plan to study Macugen treatment of macular edema due to BRVO.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks</measure>
    <time_frame>54 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized Change From Baseline in Macular Thickening Measured by OCT3 Using the Central Point of the Central Subfield</measure>
    <time_frame>54 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Parameters</measure>
    <time_frame>54 Weeks</time_frame>
    <description>Safety endpoints incuded all investigator reported ocular and systemic adverse events. All events were graded as mild moderate or severe and assessed as related or unrelated to the injection procedure and the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Subfield Thickness on OCT From Baseline to Week 54</measure>
    <time_frame>54 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Macular Volume on OCT From Baseline to Week 54</measure>
    <time_frame>54 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Pegaptanib Sodium 0.3mg (Macugen)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegaptanib Sodium 1 mg (Macugen)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaptanib sodium (Macugen)</intervention_name>
    <description>Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.</description>
    <arm_group_label>Pegaptanib Sodium 0.3mg (Macugen)</arm_group_label>
    <arm_group_label>Pegaptanib Sodium 1 mg (Macugen)</arm_group_label>
    <other_name>Macugen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Macular edema secondary to BRVO involving the foveal center in male or female patients
             at least 18 years of age

          -  Duration of BRVO macular edema less than 6 months prior to baseline visit

          -  Best corrected ETDRS visual acuity 20/40-20/320 (Snellen equivalent) using the 4
             meters testing method.

          -  Central foveal thickness greater than or equal to 250 microns using the OCT-3

          -  Less than 25% of foveal capillary ring disruption

          -  Less than 2 disc areas of capillary non-perfusion within 1000 microns of the foveal
             center

          -  Absence of hemorrhage or lipid in the foveal center

          -  Investigator comfortable deferring macular laser for 18 weeks from baseline and
             intravitreous steroid for 36 weeks from baseline

        Exclusion Criteria:

          -  Ocular conditions other than BRVO related macular edema such as significant cataract,
             diabetic retinopathy, AMD, glaucoma, uveitis, epiretinal membrane, vitreomacular
             traction or tumor.

          -  Intraocular surgery within past 3 months

          -  Significant enlargement of foveal avascular zone(&gt;25% disruption of capillary ring) or
             greater than 2 disc areas of nonperfusion within 1000 microns of foveal center.

          -  Likelihood of evidence driven indication for peripheral photocoagulation in the next 6
             months.

          -  Patients who have shown evidence of spontaneous improvement within the preceding 3
             months, as determined by an improvement of &gt;15 letters of vision or thinning of the
             Center Point on OCT of &gt;20% from baseline determination

          -  Prior grid laser within 4 months of baseline or more than one prior grid laser
             treatment.

          -  No prior intravitreous or periocular steroid injections in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Wells, III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palmetto Retina Center, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Center</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retina Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806.</citation>
    <PMID>2866759</PMID>
  </reference>
  <reference>
    <citation>Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol. 1984 Sep 15;98(3):271-82.</citation>
    <PMID>6383055</PMID>
  </reference>
  <reference>
    <citation>Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995 Oct;102(10):1425-33.</citation>
    <PMID>9097788</PMID>
  </reference>
  <reference>
    <citation>Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005 Oct;112(10):1747-57.</citation>
    <PMID>16154196</PMID>
  </reference>
  <reference>
    <citation>Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480-7.</citation>
    <PMID>7526212</PMID>
  </reference>
  <reference>
    <citation>Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002 Apr;133(4):537-43.</citation>
    <PMID>11931788</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <results_first_submitted>January 30, 2013</results_first_submitted>
  <results_first_submitted_qc>September 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Palmetto Retina Center, LLC</investigator_affiliation>
    <investigator_full_name>John A. Wells, III, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>branch retinal vein occlusion</keyword>
  <keyword>macular edema</keyword>
  <keyword>pegaptanib sodium</keyword>
  <keyword>vascular endothelial growth factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pegaptanib Sodium 0.3mg (Macugen)</title>
        </group>
        <group group_id="P2">
          <title>Pegaptanib Sodium 1 mg (Macugen)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegaptanib Sodium 0.3mg (Macugen)</title>
          <description>Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.</description>
        </group>
        <group group_id="B2">
          <title>Pegaptanib Sodium 1 mg (Macugen)</title>
          <description>Intravitreous injections of Macugen 1.0 mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.9" spread="8.2"/>
                    <measurement group_id="B2" value="77" spread="8.7"/>
                    <measurement group_id="B3" value="73.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks</title>
        <time_frame>54 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Outcome measures were assessed without regard to dosage of pegaptanib received</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks</title>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Change From Baseline in Macular Thickening Measured by OCT3 Using the Central Point of the Central Subfield</title>
        <time_frame>54 Weeks</time_frame>
        <population>Fifteen patients were enrolled in the pegaptanib 0.3 mg dose group and 5 patients were enrolled in the 1.0 mg dose group.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Outcome measures were assessed without regard to dosage of pegaptanib received</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Change From Baseline in Macular Thickening Measured by OCT3 Using the Central Point of the Central Subfield</title>
          <population>Fifteen patients were enrolled in the pegaptanib 0.3 mg dose group and 5 patients were enrolled in the 1.0 mg dose group.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-205" spread="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Parameters</title>
        <description>Safety endpoints incuded all investigator reported ocular and systemic adverse events. All events were graded as mild moderate or severe and assessed as related or unrelated to the injection procedure and the study drug.</description>
        <time_frame>54 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium 0.3mg (Macugen)</title>
            <description>Patients experiencing an ocular adverse event, in this case a retinal detachment</description>
          </group>
          <group group_id="O2">
            <title>Pegaptanib Sodium 1 mg (Macugen)</title>
            <description>Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Parameters</title>
          <description>Safety endpoints incuded all investigator reported ocular and systemic adverse events. All events were graded as mild moderate or severe and assessed as related or unrelated to the injection procedure and the study drug.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Subfield Thickness on OCT From Baseline to Week 54</title>
        <time_frame>54 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Outcome measures were assessed without regard to dosage of pegaptanib received</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Subfield Thickness on OCT From Baseline to Week 54</title>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-201" spread="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Macular Volume on OCT From Baseline to Week 54</title>
        <time_frame>54 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Outcome measures were assessed without regard to dosage of pegaptanib received</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Macular Volume on OCT From Baseline to Week 54</title>
          <units>mm cubed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pegaptanib Sodium 0.3mg (Macugen)</title>
          <description>Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.</description>
        </group>
        <group group_id="E2">
          <title>Pegaptanib Sodium 1 mg (Macugen)</title>
          <description>Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John A. Wells, III, M.D.</name_or_title>
      <organization>Palmetto Retina Center</organization>
      <phone>803-931-0077</phone>
      <email>jackwells@palmettoretina.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

